1. Home
  2. TJX vs VRTX Comparison

TJX vs VRTX Comparison

Compare TJX & VRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo TJX Companies Inc. (The)

TJX

TJX Companies Inc. (The)

N/A

Current Price

$136.64

Market Cap

146.6B

ML Signal

N/A

Logo Vertex Pharmaceuticals Incorporated

VRTX

Vertex Pharmaceuticals Incorporated

N/A

Current Price

$547.61

Market Cap

135.6B

Sector

Technology

ML Signal

N/A

Company Overview

Basic Information
Metric
TJX
VRTX
Founded
1962
1989
Country
United States
United States
Employees
N/A
N/A
Industry
Clothing/Shoe/Accessory Stores
EDP Services
Sector
Consumer Discretionary
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
146.6B
135.6B
IPO Year
1994
2006

Fundamental Metrics

Financial Performance
Metric
TJX
VRTX
Price
$136.64
$547.61
Analyst Decision
Buy
Buy
Analyst Count
23
32
Target Price
$167.85
★ $595.36
AVG Volume (30 Days)
★ 4.5M
1.5M
Earning Date
11-18-2026
11-02-2026
Dividend Yield
★ 1.40%
N/A
EPS Growth
14.32
★ 836.54
EPS
2.55
★ 10.90
Revenue
★ $29,078,407,000.00
$2,488,652,000.00
Revenue This Year
$6.01
$10.46
Revenue Next Year
$6.22
$10.53
P/E Ratio
$53.68
★ $50.25
Revenue Growth
6.04
★ 46.20
52 Week Low
$122.81
$412.27
52 Week High
$170.00
$568.67

Technical Indicators

Market Signals
Indicator
TJX
VRTX
Relative Strength Index (RSI) 45.22 57.23
Support Level $122.81 $461.04
Resistance Level $162.72 $561.54
Average True Range (ATR) 3.45 17.62
MACD -0.94 1.47
Stochastic Oscillator 14.70 63.56

Price Performance

Historical Comparison
TJX
VRTX

About TJX TJX Companies Inc. (The)

Founded in 1987, TJX Companies is the world's largest off-price apparel and home fashions retailer, operating more than 5,000 stores across nine countries. In fiscal 2026, the company generated roughly $60 billion in sales. TJX operates through four segments: Marmaxx (61% of sales), HomeGoods (17%), TJX Canada (9%), and TJX international (13%). Its off-price model emphasizes branded merchandise at meaningful discounts, driving high traffic and rapid inventory turnover.

About VRTX Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex is focused on diversifying its portfolio through Casgevy (gene-editing therapy for beta thalassemia and sickle-cell disease), Journavx (non-opioid pain drug for moderate-to-severe acute pain), and Palsonify (for acromegaly). Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases, cell therapies to deliver a functional cure for type 1 diabetes, povetacicept (for IgA nephropathy).

Share on Social Networks: